Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab for peanut allergy
NL-OMON52165Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ligelizumab in peanut allergy and food allergy (3 arms), sponsored by Novartis. Primary endpoint: Tolerance of at least 600 mg single peanut protein dose at Week 12. Started Jul 2022; status: active, not recruiting.
02
Drugs
ligelizumab
03
Conditions
peanut allergyfood allergy
Beyond the preview
Go deeper on NL-OMON52165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52165.